Mechanisms and Duration of Immunity to SARS-CoV-2

SARS-CoV-2 的免疫机制和持续时间

基本信息

批准号：
10222102
负责人：
Scott Dexter Boyd
金额：
$ 401.74万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-23 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10222102
关键词：
2019-nCoV Acute Address African American Agonist Antibodies Antigen Targeting Attention Award B-Lymphocytes Biopsy Blood COVID-19 Cancer Patient Caucasians Cells Clinical Collaborations Communities Convalescence Coronavirus Data Data Set Diagnosis Disease Elderly Evaluation Female Hispanic Americans Human Immune Immune response Immune system Immunity Immunologic Memory Immunologics Individual Infection Institution Knowledge Laboratories Longitudinal Studies Mucosal Immune Responses Mucous Membrane Nose Patient Recruitments Patients Peripheral Blood Mononuclear Cell Phenotype Physicians Plasma Plasma Cells Populations at Risk Protocols documentation Research Risk Route Science Serologic tests Serological Severity of illness Site T cell response T-Lymphocyte Testing Tissue Sample Toll-like receptors Translational Research Translations Vaccination Validation Viral Antigens adaptive immune response adaptive immunity base clinical development cohort data sharing immune checkpoint blockade interest male medically underserved medically underserved population member mucosal site novel therapeutic intervention outcome forecast pandemic disease patient population research clinical testing response tool vaccine candidate vaccine trial young adult

项目摘要

OVERALL: SUMMARY We propose the Stanford U54 SARS-CoV-2 Serological Sciences Center of Excellence (SUSS-COE) as a member of the SeroNet consortium gathered to address the urgent need for better understanding of human immune responses to the SARS-CoV-2 coronavirus pandemic that has engulfed the U.S. and the world. Our Center will be based on four scientific pillars:  Deep mechanistic analysis of the adaptive immune responses of COVID-19 patients, spanning serological, B cell and T cell responses,  Analysis of immune responses in the blood as well as mucosal sites,  Comparing immune responses induced by infection to those induced by candidate vaccines, and  Studying medically underserved, underrepresented and at-risk patient populations Within these parameters, we will attempt to determine the factors that result in effective and durable immunity to SARS-CoV-2 infection. We are dedicated to broad collaboration, rapid sharing of data and technical knowledge, nimbleness in responding to the rapidly changing pandemic, and rapid translation of research findings to CLIA Lab clinical testing and development of new therapeutic approaches. We feel these are the best routes forward for addressing gaps in our understanding of the determinants of protective immunity to SARS-CoV-2, and providing useful tools for physicians and patients.

总体：总结我们提议将斯坦福大学 U54 SARS-CoV-2 血清学科学卓越中心 (SUSS-COE) 作为 SeroNet 联盟成员齐聚一堂，解决更好地了解人类的迫切需要对席卷美国和世界的 SARS-CoV-2 冠状病毒大流行的免疫反应。我们的中心将基于四个科学支柱：  对 COVID-19 患者适应性免疫反应的深入机制分析，涵盖血清学、B 细胞和 T 细胞反应，分析血液和粘膜部位的免疫反应，比较感染引起的免疫反应与候选疫苗引起的免疫反应，以及研究医疗服务不足、代表性不足和高危患者群体在这些参数内，我们将尝试确定导致有效和持久免疫力的因素 SARS-CoV-2 感染。我们致力于广泛的合作、数据和技术知识的快速共享、敏捷性应对快速变化的流行病，并将研究成果快速转化为 CLIA 实验室临床我们认为这些是治疗方法的最佳前进方向。解决我们对 SARS-CoV-2 保护性免疫决定因素的理解差距，以及为医生和患者提供有用的工具。